- Home
- KPRX vs APRE Comparison
KPRX vs APRE Comparison
Compare KPRX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- APRE
- Stock Information
- Founded
- KPRX 1998
- APRE 2006
- Country
- KPRX United States
- APRE United States
- Employees
- KPRX N/A
- APRE N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KPRX Health Care
- APRE Health Care
- Exchange
- KPRX Nasdaq
- APRE Nasdaq
- Market Cap
- KPRX 8.7M
- APRE 9.4M
- IPO Year
- KPRX N/A
- APRE 2019
- Fundamental
- Price
- KPRX $2.93
- APRE $1.69
- Analyst Decision
- KPRX Strong Buy
- APRE Strong Buy
- Analyst Count
- KPRX 1
- APRE 1
- Target Price
- KPRX $10.00
- APRE $20.00
- AVG Volume (30 Days)
- KPRX 93.7K
- APRE 60.0K
- Earning Date
- KPRX 08-08-2025
- APRE 08-12-2025
- Dividend Yield
- KPRX N/A
- APRE N/A
- EPS Growth
- KPRX N/A
- APRE N/A
- EPS
- KPRX N/A
- APRE N/A
- Revenue
- KPRX N/A
- APRE $841,012.00
- Revenue This Year
- KPRX N/A
- APRE N/A
- Revenue Next Year
- KPRX N/A
- APRE N/A
- P/E Ratio
- KPRX N/A
- APRE N/A
- Revenue Growth
- KPRX N/A
- APRE N/A
- 52 Week Low
- KPRX $2.25
- APRE $1.41
- 52 Week High
- KPRX $4.29
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- KPRX 59.57
- APRE 46.79
- Support Level
- KPRX $2.27
- APRE $1.66
- Resistance Level
- KPRX $2.60
- APRE $1.79
- Average True Range (ATR)
- KPRX 0.18
- APRE 0.14
- MACD
- KPRX 0.03
- APRE -0.01
- Stochastic Oscillator
- KPRX 89.47
- APRE 38.89
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.